Guideline-Directed Medical Therapy in Stress-Induced Cardiomyopathy

Introduction to GDMT Continuation

The American Heart Association, American College of Cardiology, and Heart Failure Society of America provide a Class I, Level B-R recommendation that GDMT should be continued in patients with heart failure and improved ejection fraction to prevent relapse of heart failure and left ventricular dysfunction, even in asymptomatic patients 1

A landmark open-label randomized controlled trial demonstrated that phased withdrawal of heart failure medications in patients with previous dilated cardiomyopathy resulted in relapse in 40% of patients within 6 months 1
Treatment was successfully withdrawn in only 50% of patients, with the remainder experiencing significant deterioration in cardiac function, left ventricular volumes, or biomarkers 1
Relapse was rigorously defined by at least one of: LVEF reduction >10% and to <50%; LVEDV increase >10% above normal range; NT-proBNP doubling to >400 ng/L; or clinical heart failure 1

The American College of Cardiology recommends that the following medications should be continued indefinitely after EF recovery: Beta-blockers 1
The American College of Cardiology recommends that the following medications should be continued indefinitely after EF recovery: ACE inhibitors, ARBs, or ARNIs 1
The American College of Cardiology recommends that the following medications should be continued indefinitely after EF recovery: Mineralocorticoid receptor antagonists 1
The American College of Cardiology recommends that the following medications should be continued indefinitely after EF recovery: SGLT2 inhibitors 1
The American College of Cardiology recommends that the following medications should be continued indefinitely after EF recovery: Loop diuretics as needed for volume management 1

Annual echocardiographic assessment of LVEF for a minimum of several years after recovery is recommended by the American Heart Association 1
Serial NT-proBNP measurements can help detect early signs of relapse before clinical deterioration occurs 1
Monitor for worsening Kansas City Cardiomyopathy Questionnaire scores, which declined significantly with medication withdrawal in trials 1
Assess for increases in left ventricular volumes and reductions in ejection fraction at each follow-up visit 1
Clinical follow-up at least annually is recommended to assess for symptoms, change in functional status, adherence to and adequacy of lifestyle and medical interventions, and monitoring for complications 2, 3

Do not interpret symptom resolution and EF normalization as "cure"—this represents remission requiring ongoing treatment, not recovery 1
The American College of Cardiology explicitly advises against this common misconception, as normalized cardiac function does not eliminate the underlying vulnerability to relapse 1
Do not assume that normalized biomarkers and normalized LVEDV indicate it is safe to discontinue therapy—even these patients had 40% relapse rates in randomized trials 1
The absence of symptoms or abnormal findings does not predict who will relapse upon medication withdrawal 1
Avoid discontinuing GDMT based solely on patient preference to avoid medications, as the risk of relapse with potentially irreversible cardiac dysfunction outweighs medication burden 1
Shared decision-making should include explicit discussion of the 40% relapse risk within 6 months of discontinuation 1
Stress-induced cardiomyopathy has a documented recurrence rate of approximately 1-2% per year, and patients remain vulnerable to future stress-mediated cardiac dysfunction 1